Area of research
Oncology · Cognitive Neuroscience
Research interest
Research focused on Chimeric antigen receptor and Minimal residual disease, with related work in Denosumab, Lymphoma, Cytokine release syndrome. Notable publications include 'Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone', 'Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL', and 'ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after...'.
ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone